Eli Lilly and Co. (NYSE:LLY) has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's (NYSE:NVO) Ozempic.
What Happened: The study, published on the JAMA Internal Medicine website, analyzed the electronic health records of approximately 41,000 obese or overweight patients who were prescribed these drugs.
It revealed that Mounjaro users experienced a mean loss in body weight of 5.9% at three months, compared to 3.6% for Ozempic users. At six months, the mean loss was 10.1% for Mounjaro users versus 5.8% for Ozempic users.
At 12 months, the mean body weight loss was 15.3% for Mounjaro users and 8.3% for Ozempic users. The risk of gastrointestinal adverse events was similar for both drugs.
Read Also: 'I Smoked It And I Felt The Disease Stop'
Mounjaro's active ingredient is tirzepatide, while Ozempic's is semaglutide. Lilly markets tirzepatide for diabetes as Mounjaro and for weight loss as Zepbound. Similarly, Novo markets semaglutide for diabetes as Ozempic and for weight loss as Wegovy. Both tirzepatide and semaglutide belong to a class of drugs known as GLP-1s.
Why It Matters: The findings come amid increasing scrutiny and competition in the weight loss drug market. Novo Nordisk has faced criticism over the high prices of its medications, Ozempic and Wegovy. The company has disclosed that it retains about 60% of the list price in the U.S. after rebates and fees.
Additionally, a recent observational study has linked Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, to a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. This condition, which involves a loss of blood flow to the optic nerve, was highlighted in a study.
Meanwhile, in response to the growing demand for GLP-1 drugs, Novo Nordisk announced a $4.1 billion investment to expand its U.S. manufacturing operations.
Price Action: Eli Lilly and Co. stock closed at $918.00, up 0.38% on Monday. In after-hours trading, the stock increased 0.30%. Year to date, Eli Lilly's stock has risen by 55.02%.
Meanwhile, Novo Nordisk closed at $143.07, up by 0.49% on the same day. Year to date, Novo Nordisk's stock has grown by $40.96, reflecting a 40.11% increase, according to data from Benzinga Pro.
- Why Is HilleVax Stock Trading Lower On Monday?
Image Via Shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
Eli Lilly and Co.紐約證券交易所代碼：LLY）在最近的一項研究中在減肥藥物競賽中名列前茅。該研究發現，服用禮來公司Mounjaro的患者比使用諾和諾德（紐約證券交易所代碼：NVO）Ozempic的患者體重減輕得多。
發生了什麼：這項研究發表在JAMA Internal Medicine網站上，分析了大約41,000名服用這些藥物的肥胖或超重患者的電子健康記錄。
報告顯示，Mounjaro用戶在三個月內的平均體重減輕了5.9％，而Ozempic用戶的平均體重減輕了3.6％。六個月後，Mounjaro用戶的平均損失爲10.1％，而Ozempic用戶的平均損失爲5.8％。
在12個月時，Mounjaro用戶的平均體重減輕爲15.3％，Ozempic用戶的平均體重減輕爲8.3％。兩種藥物發生胃腸道不良事件的風險相似。
Mounjaro的活性成分是曲塞帕肽，而Ozempic的活性成分是索瑪魯肽。禮來公司以Mounjaro的名義銷售用於糖尿病的替西帕肽，以Zepbound的名義銷售用於減肥的替西帕肽。同樣，Novo以Ozempic的名義銷售用於糖尿病的西瑪魯肽，以Wegovy的名義銷售用於減肥的西瑪魯肽。替塞帕肽和索瑪魯肽都屬於一類被稱爲GLP-1的藥物。
爲何重要：這些發現是在減肥藥市場的審查和競爭日益激烈的情況下得出的。諾和諾德因其藥品Ozempic和Wegovy的高昂價格而受到批評。該公司透露，扣除回扣和費用後，它在美國保留了約60％的標價。
此外，最近的一項觀察性研究將諾和諾德的 GLP-1 藥物Ozempic和Wegovy與一種稱爲非動脈炎性前缺血性視神經病變（NAION）的嚴重眼部疾病聯繫起來，這種疾病可能導致視力喪失。一項研究強調了這種情況，它涉及流向視神經的血液流失。
同時，爲了應對對 GLP-1 藥物不斷增長的需求，諾和諾德宣佈投資41億美元，以擴大其在美國的製造業務。
價格走勢：禮來公司股價週一收於918.00美元，上漲0.38％。在盤後交易中，該股上漲了0.30％。今年迄今爲止，禮來公司的股票已經上漲了55.02％。
同時，諾和諾德收於143.07美元，同日上漲0.49％。根據Benzinga Pro的數據，今年迄今爲止，諾和諾德的股票增長了40.96美元，增長了40.11％。
圖片來自 Shutterstock
這個故事是使用 Benzinga Neuro 創作的，由 Kaustubh Bagalkote
